BCLI vs. CSBR, OMGA, BLUE, ATHA, DBVT, ALVR, DTIL, IKNA, GRTS, and PLX
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Champions Oncology (CSBR), Omega Therapeutics (OMGA), bluebird bio (BLUE), Athira Pharma (ATHA), DBV Technologies (DBVT), AlloVir (ALVR), Precision BioSciences (DTIL), Ikena Oncology (IKNA), Gritstone bio (GRTS), and Protalix BioTherapeutics (PLX). These companies are all part of the "biological products, except diagnostic" industry.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
Brainstorm Cell Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.
Champions Oncology has higher revenue and earnings than Brainstorm Cell Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Champions Oncology. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.04 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Champions Oncology is being referred to more favorably in the news media.
Brainstorm Cell Therapeutics received 141 more outperform votes than Champions Oncology when rated by MarketBeat users. Likewise, 63.60% of users gave Brainstorm Cell Therapeutics an outperform vote while only 60.08% of users gave Champions Oncology an outperform vote.
14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 5.5% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 45.7% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Champions Oncology's net margin of -19.76%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Champions Oncology's return on equity.
Champions Oncology has a consensus target price of $7.50, indicating a potential upside of 63.04%. Given Champions Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Champions Oncology is more favorable than Brainstorm Cell Therapeutics.
Summary
Champions Oncology beats Brainstorm Cell Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
